Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus, Tacrolimus, and Methotrexate for Prevention of Acute GVHD in Hematopoietic Stem Cell Transplantation
NCT00089037Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jun 2003
- Primary completion
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sirolimus in graft-versus-host disease (GVHD), sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Safety and Efficacy of Sirolimus up to 5 years. Started Jun 2003; status: completed.
02
Drugs
sirolimus
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00089037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00089037.